Loading...
XSHG600572
Market cap1.62bUSD
Dec 24, Last price  
4.73CNY
1D
1.07%
1Q
11.29%
Jan 2017
-35.29%
Name

Zhejiang CONBA Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHG:600572 chart
P/E
19.99
P/S
1.76
EPS
0.24
Div Yield, %
3.55%
Shrs. gr., 5y
-0.44%
Rev. gr., 5y
-0.16%
Revenues
6.73b
+12.20%
603,098,894866,407,567829,918,7491,237,594,2591,094,915,7491,406,541,5781,799,426,0842,122,816,2732,733,691,1962,924,158,4593,581,615,5465,301,970,1426,020,371,0545,293,966,7786,786,645,2926,768,292,9205,909,017,0206,150,860,5836,000,443,3936,732,797,037
Net income
592m
+65.19%
28,626,58143,627,54656,758,649106,131,69791,973,561101,216,594185,527,183280,227,613295,713,135417,369,662552,347,425440,371,501441,069,516711,116,240803,794,5060453,301,7392,017,463,206358,119,418591,572,941
CFO
899m
-22.23%
65,473,017117,647,28171,201,52579,984,20398,555,327153,393,899125,929,206188,357,115245,758,214235,355,284617,434,215831,260,038969,706,133712,266,959545,776,464925,500,5391,249,699,895889,935,2381,155,481,693898,640,724
Dividend
May 31, 20240.2 CNY/sh
Earnings
May 09, 2025

Profile

Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of traditional Chinese medicines and botanical products in China. It offers chemical medicines, Chinese patent medicines, eye health products, nutritional supplements, health supplies, healthy daily necessities and food products, and other personal care products. The company was formerly known as Lanxi Yunshan Pharmaceutical Factory and changed its name to Zhejiang CONBA Pharmaceutical Co.,Ltd. in October 1999. Zhejiang CONBA Pharmaceutical Co.,Ltd. was founded in 1969 and is headquartered in Hangzhou, China. Zhejiang CONBA Pharmaceutical Co.,Ltd. is a subsidiary of Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd.
URL
http://www.conbapharm.com/
IPO date
Apr 12, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,732,797
12.20%
6,000,443
-2.45%
6,150,861
4.09%
Cost of revenue
5,965,893
4,817,089
4,899,478
Unusual Expense (Income)
NOPBT
766,904
1,183,355
1,251,383
NOPBT Margin
11.39%
19.72%
20.34%
Operating Taxes
92,967
129,920
391,107
Tax Rate
12.12%
10.98%
31.25%
NOPAT
673,937
1,053,435
860,276
Net income
591,573
65.19%
358,119
-82.25%
2,017,463
345.06%
Dividends
(420,125)
Dividend yield
3.23%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
648,153
862,516
1,475,445
Long-term debt
306,479
338,242
13,243
Deferred revenue
154,220
140,707
Other long-term liabilities
142,033
924
923
Net debt
(3,338,592)
(2,900,616)
(2,920,886)
Cash flow
Cash from operating activities
898,641
1,155,482
889,935
CAPEX
(209,144)
Cash from investing activities
(289,052)
1,100,011
Cash from financing activities
(719,082)
FCF
1,052,940
1,186,835
685,850
Balance
Cash
2,570,009
2,468,032
2,487,258
Long term investments
1,723,216
1,633,342
1,922,316
Excess cash
3,956,585
3,801,351
4,102,031
Stockholders' equity
6,518,975
7,324,025
7,320,109
Invested Capital
4,489,000
4,727,137
4,801,472
ROIC
14.63%
22.11%
17.64%
ROCE
8.80%
13.36%
13.58%
EV
Common stock shares outstanding
2,572,056
2,570,037
2,570,037
Price
5.05
6.77%
4.73
-5.40%
5.00
6.16%
Market cap
12,988,884
6.85%
12,156,277
-5.40%
12,850,187
8.34%
EV
9,958,871
9,665,834
10,260,634
EBITDA
1,100,028
1,460,838
1,528,977
EV/EBITDA
9.05
6.62
6.71
Interest
37,432
49,472
72,973
Interest/NOPBT
4.88%
4.18%
5.83%